AU2016215676B2 - Anti-surrogate light chain antibodies - Google Patents

Anti-surrogate light chain antibodies Download PDF

Info

Publication number
AU2016215676B2
AU2016215676B2 AU2016215676A AU2016215676A AU2016215676B2 AU 2016215676 B2 AU2016215676 B2 AU 2016215676B2 AU 2016215676 A AU2016215676 A AU 2016215676A AU 2016215676 A AU2016215676 A AU 2016215676A AU 2016215676 B2 AU2016215676 B2 AU 2016215676B2
Authority
AU
Australia
Prior art keywords
sequence
antibody
human
light chain
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016215676A
Other languages
English (en)
Other versions
AU2016215676A1 (en
Inventor
Lawrence Horowitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Children's Health Care D/b/a Children's Minnesota
Original Assignee
Childrens Health Care D/b/a Childrens Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Health Care D/b/a Childrens Minnesota filed Critical Childrens Health Care D/b/a Childrens Minnesota
Publication of AU2016215676A1 publication Critical patent/AU2016215676A1/en
Application granted granted Critical
Publication of AU2016215676B2 publication Critical patent/AU2016215676B2/en
Assigned to CHILDREN'S HEALTH CARE D/B/A CHILDREN'S MINNESOTA reassignment CHILDREN'S HEALTH CARE D/B/A CHILDREN'S MINNESOTA Request for Assignment Assignors: I2 PHARMACEUTICALS, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2016215676A 2015-02-02 2016-01-27 Anti-surrogate light chain antibodies Active AU2016215676B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562111018P 2015-02-02 2015-02-02
US62/111,018 2015-02-02
PCT/US2016/015166 WO2016126488A1 (en) 2015-02-02 2016-01-27 Anti-surrogate light chain antibodies

Publications (2)

Publication Number Publication Date
AU2016215676A1 AU2016215676A1 (en) 2017-08-10
AU2016215676B2 true AU2016215676B2 (en) 2021-12-02

Family

ID=56564528

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016215676A Active AU2016215676B2 (en) 2015-02-02 2016-01-27 Anti-surrogate light chain antibodies

Country Status (10)

Country Link
US (1) US10858448B2 (https=)
EP (2) EP3253793A4 (https=)
JP (1) JP2018507254A (https=)
KR (1) KR102590740B1 (https=)
CN (1) CN107849123A (https=)
AU (1) AU2016215676B2 (https=)
CA (2) CA3185253A1 (https=)
HK (1) HK1247941A1 (https=)
IL (1) IL253579A0 (https=)
WO (1) WO2016126488A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016126488A1 (en) 2015-02-02 2016-08-11 Sea Lane Biotechnologies, Llc Anti-surrogate light chain antibodies
HK1250146A1 (zh) 2015-02-05 2018-11-30 Stc.Unm 抗前-bcr拮抗剂和方法
CN110352068A (zh) 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
CA3128502A1 (en) * 2019-02-01 2020-08-06 Novarock Biotherapeutics, Ltd. Anti-claudin 18 antibodies and methods of use thereof
US12134655B2 (en) * 2019-04-30 2024-11-05 Absci Corporation Cancer associated antibody compositions and methods of use
CN112300282A (zh) * 2020-11-03 2021-02-02 南京北恒生物科技有限公司 靶向cd7的人源化抗体及其用途
US12285494B2 (en) 2021-02-16 2025-04-29 Children's Health Care Methods for treating B-ALL by administering a pre-BCR complex antagonist
WO2024077104A2 (en) * 2022-10-04 2024-04-11 Mink Therapeutics, Inc. Fibroblast activation protein (fap) car-invariant natural killer t cells and uses thereof
WO2025212740A1 (en) * 2024-04-03 2025-10-09 Mink Therapeutics, Inc. Composition and methods for treating colorectal cancer liver metastasis (crc liver mets)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335175B1 (en) * 1997-07-29 2002-01-01 Sumitomo Electric Industries, Ltd. Anti-human pre-B cell receptor antibody
US20030215453A1 (en) * 2002-05-14 2003-11-20 Dedera Douglas A. Methods of therapy and diagnosis using immunotargeting of cells expressing VpreB1 protein

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US62950A (en) 1867-03-19 Improvement in apparatus foe the manufacture of vinegar
US2010A (en) 1841-03-18 Machine foe
JPS60222842A (ja) 1984-04-19 1985-11-07 Fuji Photo Film Co Ltd ハロゲン化銀写真乳剤およびその製造方法
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
EP0269127B1 (en) 1986-11-27 1994-02-23 F. Hoffmann-La Roche Ag Nucleotide sequences which are selectively expressed in pre-B cells and probes therefor
US5182205A (en) 1986-11-27 1993-01-26 Hoffmann-La Roche Inc. Nucleotide sequences which are selectively expressed in pre-B cells and probes therefor
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
US6492160B1 (en) 1991-05-15 2002-12-10 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US7067284B1 (en) 1992-01-27 2006-06-27 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US5233409A (en) 1992-02-25 1993-08-03 Schwab Karl W Color analysis of organic constituents in sedimentary rocks for thermal maturity
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9225453D0 (en) 1992-12-04 1993-01-27 Medical Res Council Binding proteins
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US6326155B1 (en) 1995-03-20 2001-12-04 Dyax Corp. Engineering affinity ligands for macromolecules
US6696248B1 (en) 1995-08-18 2004-02-24 Morphosys Ag Protein/(poly)peptide libraries
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
GB9712818D0 (en) 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
JPH11133028A (ja) * 1997-10-29 1999-05-21 Sumitomo Electric Ind Ltd 抗ヒトプレｂ細胞レセプター抗体
GB2377997A (en) * 2001-07-24 2003-01-29 Bookham Technology Plc Connection of a non-perpendicular optical fibre to an optical device
JP4602614B2 (ja) 2001-09-26 2010-12-22 アイシン精機株式会社 自動車用ドア
WO2005063819A2 (en) 2003-12-23 2005-07-14 Crucell Holland B.V. Human binding molecule against cd1a
EP2069558B1 (en) 2006-10-02 2013-05-01 Sea Lane Biotechnologies,llc. Design and construction of diverse synthetic peptide and polypeptide libraries
BRPI0809435A2 (pt) 2007-03-27 2014-09-09 Sea Lane Biotechnologies, Llc Constructos e bibliotecas que compreendem sequências de cadeia leve substituida de anticorpos
WO2010006286A2 (en) 2008-07-11 2010-01-14 Sea Lane Biotechnologies, Llc Constructs and libraries comprising antibody surrogate kappa light chain sequences
KR101829073B1 (ko) * 2009-06-26 2018-02-13 아이2 파마슈티컬스, 인크. 대리 경쇄의 발현
CA2823776A1 (en) 2011-01-06 2012-07-12 Dyax Corp. Plasma kallikrein binding proteins
WO2016126488A1 (en) 2015-02-02 2016-08-11 Sea Lane Biotechnologies, Llc Anti-surrogate light chain antibodies
HK1250146A1 (zh) * 2015-02-05 2018-11-30 Stc.Unm 抗前-bcr拮抗剂和方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335175B1 (en) * 1997-07-29 2002-01-01 Sumitomo Electric Industries, Ltd. Anti-human pre-B cell receptor antibody
US20030215453A1 (en) * 2002-05-14 2003-11-20 Dedera Douglas A. Methods of therapy and diagnosis using immunotargeting of cells expressing VpreB1 protein

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SEON-HEE YIM ET AL, "The potential role ofgene copy number variation in susceptibility to rheumatoid arthritis", MOLECULAR IMMUNOLOGY, vol. 48, (2010-11-02), pages 1338 - 1343 *

Also Published As

Publication number Publication date
EP3253793A4 (en) 2018-11-14
HK1247941A1 (zh) 2018-10-05
IL253579A0 (en) 2017-09-28
CA2975346A1 (en) 2016-08-11
WO2016126488A1 (en) 2016-08-11
EP4177267A1 (en) 2023-05-10
JP2018507254A (ja) 2018-03-15
AU2016215676A1 (en) 2017-08-10
US20180265594A1 (en) 2018-09-20
CA3185253A1 (en) 2016-08-11
EP3253793A1 (en) 2017-12-13
KR20170120120A (ko) 2017-10-30
KR102590740B1 (ko) 2023-10-18
CN107849123A (zh) 2018-03-27
US10858448B2 (en) 2020-12-08

Similar Documents

Publication Publication Date Title
AU2016215676B2 (en) Anti-surrogate light chain antibodies
EP2528948B1 (en) Novel lowered affinity antibodies and methods of making the same
CA2823044C (en) Express humanization of antibodies
EP2989204B1 (en) Isolation of therapeutic target specific vnar domains to icosl
JP7663977B2 (ja) 抗ｐｄ―ｌ１抗体およびその用途
CA2507494A1 (en) Rationally designed antibodies
US20100062950A1 (en) Constructs and libraries comprising antibody surrogate kappa light chain sequences
US10919955B2 (en) Rodent combinatorial antibody libraries
WO2009142460A2 (en) Antibody-peptide fused synergibody
CN101389791A (zh) 融合蛋白文库的产生和筛选方法及其应用
JP6918399B2 (ja) 抗体ナイーブライブラリーを生成する方法、前記ライブラリー及びその用途
US20100233167A1 (en) Chain reaction creating oligomers from repeat units of binding molecules
HK40090806A (en) Anti-surrogate light chain antibodies
US20110245100A1 (en) Generation of antibodies to an epitope of interest
HK1159132A (en) Constructs and libraries comprising antibody surrogate kappa light chain sequences

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: CHILDREN'S HEALTH CARE D/B/A CHILDREN'S MINNESOTA

Free format text: FORMER APPLICANT(S): I2 PHARMACEUTICALS, INC.

FGA Letters patent sealed or granted (standard patent)